Cargando…
Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
We present two cases of pulmonary pleomorphic carcinoma (PPC) treated with Nivolumab. A 57‐year‐old man presented with a 3.5‐cm mass in the left lower lobe. Left lower lobectomy and lymph node dissection were performed. Histological diagnosis was stage IIIA (pT2bN2M0) PPC. The tumour relapsed two mo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702315/ https://www.ncbi.nlm.nih.gov/pubmed/31452896 http://dx.doi.org/10.1002/rcr2.477 |
_version_ | 1783445203186614272 |
---|---|
author | Ota, Takahiro Niho, Seiji Kirita, Keisuke Ishii, Genichiro Tsuboi, Masahiro Goto, Koichi |
author_facet | Ota, Takahiro Niho, Seiji Kirita, Keisuke Ishii, Genichiro Tsuboi, Masahiro Goto, Koichi |
author_sort | Ota, Takahiro |
collection | PubMed |
description | We present two cases of pulmonary pleomorphic carcinoma (PPC) treated with Nivolumab. A 57‐year‐old man presented with a 3.5‐cm mass in the left lower lobe. Left lower lobectomy and lymph node dissection were performed. Histological diagnosis was stage IIIA (pT2bN2M0) PPC. The tumour relapsed two months later and he was treated with carboplatin and paclitaxel, but his condition became progressive and nonresponsive after one cycle. We used nivolumab as second line. Repeat chest X‐ray showed impressive reduction of relapse lesions seven days after the start of nivolumab therapy. Our second case is a 50‐year‐old man who presented with a 3.7‐cm mass in the right lower lobe and submucosal tumour in the colon. Endobronchial ultrasound‐guided transbronchial needle aspiration biopsy (EBUS‐TBNA) and colon biopsy yield the diagnosis of PPC and metastatic colon cancer. He was treated with cisplatin plus pemetrexed. His disease proved resistant and we used nivolumab as second line. He showed partial response following four cycles. |
format | Online Article Text |
id | pubmed-6702315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-67023152019-08-26 Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components Ota, Takahiro Niho, Seiji Kirita, Keisuke Ishii, Genichiro Tsuboi, Masahiro Goto, Koichi Respirol Case Rep Case Reports We present two cases of pulmonary pleomorphic carcinoma (PPC) treated with Nivolumab. A 57‐year‐old man presented with a 3.5‐cm mass in the left lower lobe. Left lower lobectomy and lymph node dissection were performed. Histological diagnosis was stage IIIA (pT2bN2M0) PPC. The tumour relapsed two months later and he was treated with carboplatin and paclitaxel, but his condition became progressive and nonresponsive after one cycle. We used nivolumab as second line. Repeat chest X‐ray showed impressive reduction of relapse lesions seven days after the start of nivolumab therapy. Our second case is a 50‐year‐old man who presented with a 3.7‐cm mass in the right lower lobe and submucosal tumour in the colon. Endobronchial ultrasound‐guided transbronchial needle aspiration biopsy (EBUS‐TBNA) and colon biopsy yield the diagnosis of PPC and metastatic colon cancer. He was treated with cisplatin plus pemetrexed. His disease proved resistant and we used nivolumab as second line. He showed partial response following four cycles. John Wiley & Sons, Ltd 2019-08-20 /pmc/articles/PMC6702315/ /pubmed/31452896 http://dx.doi.org/10.1002/rcr2.477 Text en © 2019 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Case Reports Ota, Takahiro Niho, Seiji Kirita, Keisuke Ishii, Genichiro Tsuboi, Masahiro Goto, Koichi Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components |
title | Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components |
title_full | Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components |
title_fullStr | Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components |
title_full_unstemmed | Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components |
title_short | Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components |
title_sort | impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702315/ https://www.ncbi.nlm.nih.gov/pubmed/31452896 http://dx.doi.org/10.1002/rcr2.477 |
work_keys_str_mv | AT otatakahiro impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents AT nihoseiji impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents AT kiritakeisuke impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents AT ishiigenichiro impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents AT tsuboimasahiro impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents AT gotokoichi impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents |